FTC Warns REMS Abuse Not Safe From Antitrust Law
By Melissa Lipman ( June 19, 2014, 8:54 PM EDT) -- The Federal Trade Commission warned in an amicus filing in New Jersey federal court Tuesday that generic-drug makers should be allowed to sue brand-name companies under antitrust laws for allegedly gaming federal drug safety measures — known as risk evaluation and mitigation strategies programs — in Mylan Pharmaceuticals Inc.'s antitrust suit against Celgene Corp....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.